The FDA last week approved AbbVie’s injectable Skyrizi for the treatment of plaque psoriasis. AbbVie’s Humira pen is one of the most advantaged therapies for the treatment of plaque psoriasis, holding preferred status for 9% of covered lives, which grows to 60% including prior authorization and step therapy. AbbVie may soon be reckoning with an onslaught of biosimilar competition to Humira, as the drug’s patent expired in Europe at the end of 2018.

SOURCE: MMIT Analytics, as of 4/26/19